Compugen(CGEN)
Search documents
Compugen(CGEN) - 2023 Q4 - Annual Report
2024-03-04 16:00
Any dividends distributed to "foreign companies", as defined in the Law, deriving from income from the Technological Enterprises will be subject, under certain conditions, including holding at least 90% of the share capital, to tax at a rate of 4%. Use of our U.S. net operating losses may be subject to substantial annual limitation due to the "change in ownership" provisions of the Code and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilizatio ...
Compugen(CGEN) - 2023 Q4 - Annual Report
2024-03-04 16:00
Compugen Reports Fourth Quarter and Full Year 2023 Results HOLON, ISRAEL, March 5, 2024 - Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today reported financial results for the fourth quarter and full year 2023 and provided a corporate update. Dr. Cohen-Dayag continued, "In 2023, our partner AstraZeneca continued to make progress advancing rilvegostomig, a PD-1/TIGIT bispecific antibody, the TIGIT component of which i ...
Is a Surprise Coming for Compugen (CGEN) This Earnings Season?
Zacks Investment Research· 2024-02-29 15:01
Investors are always looking for stocks that are poised to beat at earnings season and Compugen Ltd. (CGEN) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Compugen is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indica ...
Compugen (CGEN) is a Great Momentum Stock: Should You Buy?
Zacks Investment Research· 2024-02-21 18:01
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...
Compugen(CGEN) - 2023 Q3 - Earnings Call Transcript
2023-11-07 19:29
Compugen Ltd. (NASDAQ:CGEN) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Yvonne Naughton – Head-Investor Relations and Corporate Communications Anat Cohen-Dayag – President and Chief Executive Officer Alberto Sessa – Chief Financial Officer Henry Adewoye – Chief Medical Officer Pierre Ferre – Vice President-Preclinical Development Conference Call Participants Steve Willey – Stifel Operator Ladies and gentlemen, thank you for joining us today. Welcome to CompugenÂ's Third ...
Compugen(CGEN) - 2023 Q2 - Earnings Call Transcript
2023-08-07 18:40
Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Alberto Sessa - Chief Financial Officer Eran Ophir - Chief Scientific Officer Stephen Willey - Stifel Financial Corp. Tony Butler - EF Hutton Ladies and gentlemen, thank you for joining us today. Welcome to CompugenÂ's Second Quarter 2023 Results Conference Call. At this time, all participants are in a listen-only mode. As a reminder, todayÂ's call is being recorded. An audio webcast of this call will be made avai ...
Compugen(CGEN) - 2023 Q1 - Earnings Call Transcript
2023-05-15 18:21
We recognize the importance of cash efficiency and we are disciplined in how we deploy our cash resources, making sure we will focus on reaching key milestones with our available cash runway at least through the end of 2024. It is important to emphasize that this does not include any potential cash inflows, including potential milestones payment from our collaborator AstraZeneca. Expenses for the first quarter of 2023 were in line with our plans. R&D expenses for the first quarter of 2023 were $7.4 million, ...
Compugen(CGEN) - 2022 Q4 - Earnings Call Transcript
2023-02-27 18:10
Compugen Ltd. (NASDAQ:CGEN) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Yvonne Naughton - Head, IR and Corporate Communications Anat Cohen-Dayag - President and CEO Henry Adewoye - Chief Medical Officer Eran Ophir - SVP, Research and Drug Discovery Alberto Sessa - CFO Conference Call Participants Stephen Willey - Stifel Mark Breidenbach - Oppenheimer Asthika Goonewardene - Truist Securities Daina Graybosch - SVB Securities Charles Butler - EF Hutton Operator Ladies and ...
Compugen(CGEN) - 2022 Q4 - Annual Report
2023-02-27 16:00
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or an emerging growth company. See definitio ...
Compugen(CGEN) - 2022 Q3 - Earnings Call Presentation
2022-11-15 06:15
om pugen FROM CODE TO CURE® Corporate Overview 14 November 2022 מפככפכדתכרכוכ DOCTCTCTCTCCC Safe Harbor Statement This presentation contains "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," ...